FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Secti	on 30(h) o	of the	Investmer	nt Cor	mpany Act	of 1940							
1. Name and Address of Reporting Person* Simon, Christopher						2. Issuer Name <b>and</b> Ticker or Trading Symbol HAEMONETICS CORP [ HAE ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Simon, Christopher														X				10% Ov	vner
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)							X	Officer below)	(give title		Other (specify below)		
125 SUMMER STREET						05/16/2022							President & CEO						
(Street)		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)								
BOSTO	N M	A	02110											X Form filed by One Reporting Person					
(City)	(S	tate)	(Zip)		-								Form filed by More than One Reporting Person						
(1.9)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
4 Title of f	Pagurity (Inc.					_			3.		<del>.</del>				5. Amou		6 0	vnership	7. Nature
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr. 5		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securition Beneficion Owned		es Fo fally (D Following (I)		n: Direct r Indirect istr. 4)	of Indirect Beneficial Ownership	
									Code	v	Amount	(A)	or P	rice	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common Stock 05/16/					6/202	2022		S <sup>(1)</sup>		832(1	) Е		\$56.1	1 191,327(2		7 <sup>(2)</sup> D			
Common Stock 05/16/					6/202	2022		A		26,041	(3) A (4)		(4)	217,368(2)		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
(e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (l 8)				6. Date Exercise Expiration Date (Month/Day/Yea		•	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal	ole [	Expiration Date	Title	or	ount nber ires					
Non- qualified Stock Option (Right to Buy)	\$57.6	05/16/2022			A		60,891		(5)		05/16/2029	Commor Stock	60,	891	\$0	60,893	1	D	

## **Explanation of Responses:**

- 1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.
- 3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- 4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- 5. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

/s/ Thomas V. Powers, attorney- 05/18/2022 in-fact for Mr. Simon

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.